BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Summary by AI BETAClose X

BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci, will establish an independent company focused on next-generation mRNA innovations, with a management transition expected by the end of 2026. BioNTech plans to contribute related rights and mRNA technologies to this new entity in exchange for a minority stake, aiming to maximize value for both patients and shareholders by allowing each company to pursue distinct strategic priorities. BioNTech will continue to focus on its late-stage clinical pipeline, expecting 15 ongoing Phase 3 oncology trials by year-end 2026 and multiple late-stage data readouts. Binding agreements for the new company are anticipated by the end of the first half of 2026.

Disclaimer*

UK 100

Latest directors dealings